Global Leading Market Research Publisher QYResearch announces the release of its latest report “Starch-based Micropellet Cores – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Starch-based Micropellet Cores market, including market size, share, demand, industry development status, and forecasts for the next few years.
For pharmaceutical formulation scientists, drug developers, and oral solid dosage manufacturers, the selection of appropriate excipients for controlled-release and sustained-release formulations is critical to achieving optimal therapeutic outcomes while ensuring patient safety and regulatory compliance. Traditional synthetic excipients, while functional, may raise concerns regarding biocompatibility, environmental impact, and long-term safety. Starch-based micropellet cores address these challenges by providing drug carriers made primarily from starch—a natural, biodegradable polymer with excellent moldability and biocompatibility. Used widely in oral sustained-release and controlled-release preparations, these micropellets encapsulate active pharmaceutical ingredients (APIs) for gradual release, ensuring prolonged therapeutic effects and reduced side effects while leveraging the inherent safety of natural polymers for gastrointestinal drug delivery. The global market for starch-based micropellet cores, valued at US$84 million in 2025, is projected to reach US$123 million by 2032, growing at a compound annual growth rate (CAGR) of 5.7%. With global production reaching approximately 11,005 tons in 2024 and average pricing around US$7,360 per ton, the sector reflects steady growth driven by increasing demand for natural, biodegradable excipients, the expansion of generic controlled-release formulations, and the focus on patient-centric drug development.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6098150/starch-based-micropellet-cores
Market Segmentation and Product Architecture
The pharmaceutical excipient market is structured by particle size and application domain, each with distinct release profile characteristics:
- By Type (Particle Size): The market segments into Particle Size Below 500 μm, Particle Size 500-1000 μm, and Particle Size Above 1000 μm. Particles sized 500-1000 μm currently account for the largest market share, offering optimal balance of flowability, compressibility, and drug release characteristics for most controlled-release tablet and capsule formulations. Below 500 μm particles provide faster release profiles suitable for immediate or rapid-release applications, while above 1000 μm particles enable extended release profiles for once-daily or twice-daily dosing regimens. Particle size selection directly impacts surface area available for drug release, with smaller particles generally providing faster dissolution rates.
- By Application (Formulation Type): The market segments into Tablet and Capsule applications. Tablet applications currently account for the larger market share, with starch-based micropellet cores incorporated into compressed tablets for controlled-release oral solid dosage forms. Capsule applications represent a growing segment, with micropellet cores filled into hard gelatin or HPMC capsules, offering formulation flexibility and enabling combination products with multiple drug layers or release profiles.
Competitive Landscape and Recent Industry Developments
The competitive landscape features a mix of global excipient leaders and specialized natural polymer manufacturers. Key players profiled include Colorcon, JRS, FREUND Corp, NB Entrepreneurs, Meenaxy Pharma Private Limited, Anhui Sunhere Pharmaceutical Excipients, Asahi Kasei Chemicals, Yuekang Pharmaceutical Group, Hangzhou Gaocheng Biotech & Health, Jiangsu Dongsheng Pharmaceutical Technology, and Hainan Poly Pharm. A significant trend observed over the past six months is the accelerated development of modified starch micropellet cores with enhanced functionality for controlled-release applications. Manufacturers have introduced cross-linked and pregelatinized starch formulations that offer improved mechanical strength, consistent release profiles, and enhanced compatibility with a broader range of APIs.
Additionally, the market has witnessed notable advancement in multi-particulate technology and coating systems for starch-based cores. Advanced coating technologies enable precise control of drug release profiles, including enteric protection and targeted delivery, while maintaining the natural, biodegradable characteristics of starch-based carriers.
Exclusive Industry Perspective: Divergent Requirements in Natural vs. Synthetic Excipient Selection
A critical analytical distinction emerging within the pharmaceutical excipient market is the divergence between requirements for natural polymer-based micropellet cores versus synthetic alternatives. In natural polymer applications (starch-based), the emphasis is on biodegradability, biocompatibility, and clean-label positioning. Starch-based cores are preferred for formulations where natural sourcing aligns with patient expectations or where enhanced gastrointestinal tolerance is required. According to recent excipient data, starch-based carriers demonstrate excellent biocompatibility with minimal risk of adverse reactions, making them suitable for sensitive patient populations including pediatrics and geriatrics.
In synthetic excipient applications, requirements shift toward precise performance characteristics, extended release profiles, and established regulatory acceptance. While synthetic excipients may offer more predictable release kinetics, starch-based cores provide the advantages of natural sourcing, biodegradability, and reduced environmental impact. Recent case studies from drug developers demonstrate that starch-based micropellets have achieved bioequivalence to synthetic-based controlled-release formulations while offering enhanced patient acceptance through natural ingredient profiles.
Technical Innovation and Formulation Versatility
Despite the natural origin of starch, the pharmaceutical formulation industry continues to advance through starch modification and processing innovation. Starch modification technologies have become a key differentiator, with pregelatinization, cross-linking, and co-processing with other excipients enabling enhanced functionality, including improved flowability, compressibility, and consistent release profiles.
Another evolving technical frontier is the development of patient-friendly and specialized formulations using starch-based micropellets. Taste-masking coatings and orally disintegrating formulations expand the application of starch-based cores for pediatric, geriatric, and dysphagia populations, addressing unmet needs in patient-centric drug delivery.
Market Dynamics and Growth Drivers
The pharmaceutical development sector is benefiting from several structural trends supporting starch-based micropellet adoption. The growing preference for natural and biodegradable excipients in pharmaceutical formulations aligns with patient expectations and environmental considerations. The expansion of the generic pharmaceutical market, with controlled-release products representing a significant portion of generic pipeline, drives demand for reliable, cost-effective excipient platforms. The focus on patient adherence and reduced dosing frequency favors development of once-daily controlled-release formulations. Additionally, the need for formulation flexibility in combination products and fixed-dose combinations supports the use of multi-particulate pellet technologies.
Conclusion
The global starch-based micropellet cores market represents a growing segment within pharmaceutical excipients, offering natural, biodegradable alternatives for controlled-release and sustained-release oral solid dosage forms. As the demand for natural excipients increases, as patient-centric formulation development expands, and as the need for reliable, biocompatible drug carriers grows, the market for starch-based micropellet cores will continue to expand. The forthcoming QYResearch report provides comprehensive segmentation analysis, regional market sizing, technology assessments, and strategic profiles of key manufacturers, equipping stakeholders with actionable intelligence to navigate this specialized pharmaceutical excipient market.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
